Abstract

Subthalamic beta band activity (13–35 Hz) is known as a real-time correlate of motor symptom severity in Parkinson’s disease (PD) and is currently explored as a feedback signal for closed-loop deep brain stimulation (DBS). Here, we investigate the interaction of movement, dopaminergic medication, and deep brain stimulation on subthalamic beta activity in PD patients implanted with sensing-enabled, implantable pulse generators. We recorded subthalamic activity from seven PD patients at rest and during repetitive movements in four conditions: after withdrawal of dopaminergic medication and DBS, with medication only, with DBS only, and with simultaneous medication and DBS. Medication and DBS showed additive effects in improving motor performance. Distinct effects of each therapy were seen in subthalamic recordings, with medication primarily suppressing low beta activity (13–20 Hz) and DBS being associated with a broad decrease in beta band activity (13–35 Hz). Movement suppressed beta band activity compared to rest. This suppression was most prominent when combining medication with DBS and correlated with motor improvement within patients. We conclude that DBS and medication have distinct effects on subthalamic beta activity during both rest and movement, which might explain their additive clinical effects as well as their difference in side-effect profiles. Importantly, subthalamic beta activity significantly correlated with motor symptoms across all conditions, highlighting its validity as a feedback signal for closed-loop DBS.

Details

Title
Modulation of subthalamic beta oscillations by movement, dopamine, and deep brain stimulation in Parkinson’s disease
Author
Mathiopoulou, Varvara 1   VIAFID ORCID Logo  ; Lofredi, Roxanne 2   VIAFID ORCID Logo  ; Feldmann, Lucia K. 2   VIAFID ORCID Logo  ; Habets, Jeroen 1 ; Darcy, Natasha 1   VIAFID ORCID Logo  ; Neumann, Wolf-Julian 1   VIAFID ORCID Logo  ; Faust, Katharina 3 ; Schneider, Gerd-Helge 3 ; Kühn, Andrea A. 4   VIAFID ORCID Logo 

 Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
 Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Berlin Institute of Health at Charité Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.484013.a) 
 Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurosurgery, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
 Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Charité Universitätsmedizin Medicine, Berlin School of Mind and Brain, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Charité Universitätsmedizin, NeuroCure Clinical Research Centre, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); German Center for Degenerative Diseases, DZNE, Berlin, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426) 
Pages
77
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23738057
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3033747871
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.